1. Retrospective mass spectrometric analysis of wastewater-fed mesocosms to assess the degradation of drugs and their human metabolites
- Author
-
Sandra Pérez, Laia Sabater-Liesa, Damià Barceló, Nicola Montemurro, Antoni Ginebreda, Peter Eichhorn, Ministerio de Ciencia e Innovación (España), Montemurro, Nicola, Ginebreda, Antonio, Barceló, Damià, Montemurro, Nicola [0000-0002-7496-203X], Ginebreda, Antonio [0000-0003-4714-2850}, and Barceló, Damià [0000-0002-8873-0491]
- Subjects
Drug ,Ketoprofen ,Environmental Engineering ,Human metabolites ,Health, Toxicology and Mutagenesis ,Atorvastatin ,media_common.quotation_subject ,0211 other engineering and technologies ,02 engineering and technology ,Wastewater ,010501 environmental sciences ,01 natural sciences ,chemistry.chemical_compound ,Biotransformation ,medicine ,Humans ,Environmental Chemistry ,Waste Management and Disposal ,Ecosystem ,Retrospective Studies ,0105 earth and related environmental sciences ,media_common ,021110 strategic, defence & security studies ,Chromatography ,Mesocosm ,Pollution ,Norcocaine ,Pharmaceutical Preparations ,Valsartan ,chemistry ,Transformation products ,Pharmaceuticals ,Natural attenuation ,Water Pollutants, Chemical ,Drug metabolism ,Environmental Monitoring ,medicine.drug - Abstract
Temporary rivers become dependent on wastewater effluent for base flows, which severely impacts river ecosystems through exposure to elevated levels of nutrients, dissolved organic matter, and organic micropollutants. However, biodegradation processes occurring in these rivers can be enhanced by wastewater bacteria/biofilms. Here, we evaluated the attenuation of pharmaceuticals and their human metabolites performing retrospective analysis of 120 compounds (drugs, their metabolites and transformation products) in mesocosm channels loaded with wastewater effluents twice a week for a period of 31 days. Eighteen human metabolites and seven biotransformation products were identified with high level of confidence. Compounds were classified into five categories. Type-A: recalcitrant drugs and metabolites (diclofenac, carbamazepine and venlafaxine); Type-B: degradable drugs forming transformation products (TPs) (atenolol, sitagliptin, and valsartan); Type-C: drugs for which no known human metabolites or TPs were detected (atorvastatin, azithromycin, citalopram, clarithromycin, diltiazem, eprosartan, fluconazole, ketoprofen, lamotrigine, lormetazepam, metformin, telmisartan, and trimethoprim); Type-D: recalcitrant drug metabolites (4-hydroxy omeprazole sulfide, erythro/threo-hydrobupropion, and zolpidem carboxylic acid); Type-E: unstable metabolites whose parent drug was not detectable (norcocaine, benzolylecgonine, and erythromycin A enol ether). Noteworthy was the valsartan acid formation from valsartan with transient formation of TP-336., This study has been financially supported by the EU through the PRIMA project (INWAT 201980E121). This work was supported by the Spanish Ministry of Science and Innovation (Project CEX2018-000794-S). The authors also acknowledge SCIEX for providing the loan instrument LC/HRMS QTOF X500R. The EU is not liable for any use that may be made of the information contained therein.
- Published
- 2021